Why this chain matters

ORANGE (ORANY) has a mapped ChainSifter graph with 14 supplier links and 14 customer links. That makes it useful for investors trying to understand who benefits when ORANY performs well, and who may be exposed if demand or execution weakens.

The point is not to treat every edge as equal. The useful signal is the shape of the network: named suppliers, named customers, confidence levels, and filing language that shows where business dependence may sit.

Supplier exposure

The supplier side shows the companies and entities most directly tied to ORANY's operating base. Higher-confidence links deserve the first review because they are the relationships most likely to matter when margins, production, procurement, or delivery timelines change.

  • First Financial Bankshares, Inc. (FFIN) - confidence 72%.
  • Palvella Therapeutics, Inc. (PVLA) - confidence 72%.
  • Aclaris Therapeutics, Inc. (ACRS) - confidence 72%.
  • Amphastar Pharmaceuticals, Inc. (AMPH) - confidence 72%.
  • Bogota Financial Corp. (BSBK) - confidence 72%.
  • Charlie's Holdings, Inc. (CHUC) - confidence 72%.
  • Direct Digital Holdings, Inc. (DRCT) - confidence 72%.
  • Harmony Biosciences Holdings, Inc. (HRMY) - confidence 72%.

Customer and demand signals

The customer side is where revenue concentration and downstream demand risk usually show up first. If a customer relationship is central to the graph, a change in that customer's spending or inventory cycle can move through the chain quickly.

  • Amphastar Pharmaceuticals, Inc. (AMPH) - confidence 72%.
  • Borqs Technologies, Inc. (BRQSF) - confidence 72%.
  • Clean Energy Fuels Corp. (CLNE) - confidence 72%.
  • Healthy Extracts Inc. (HYEX) - confidence 72%.
  • IDT Corporation (IDT) - confidence 72%.
  • IGC Pharma, Inc. (IGC) - confidence 72%.
  • Immunome, Inc. (IMNM) - confidence 72%.
  • Ironwood Pharmaceuticals, Inc. (IRWD) - confidence 72%.

Filing evidence

ChainSifter is most useful when the map is tied back to source language. These excerpts are the evidence trail behind the graph and should be reviewed before treating a relationship as investable signal.

  • First Financial Bankshares, Inc.: Reciprocal relationship from FFIN graph: le, Keller, Kingwood, Lumberton, Magnolia, Mauriceville, Merkel, Midlothian, Mineral Wells, Montgomery, Moran, New Waverly, Newton, Odessa, Orange, Palacios, Port Arthur, Ranger, Rising Star, Roby, Southlake, Spring, Sw
  • ORANY: Reciprocal relationship from CYCN graph: rovides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity for both drugs and biologics, and also unexpired Orange Book listed patents in the case o
  • Palvella Therapeutics, Inc.: Reciprocal relationship from PVLA graph: ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summary of material factors that make an investment in our common stock speculative or risky. Importantly,
  • Aclaris Therapeutics, Inc.: Reciprocal relationship from ACRS graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from ACRS graph: are and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”), to a stricter standard such that a person or ent
  • Amphastar Pharmaceuticals, Inc.: Reciprocal relationship from AMPH graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from AMPH graph: may result in more rigorous coverage criteria, and less favorable payment methodologies, or other downward pressure on coverage and paym

Who benefits and who is exposed

If ORANGE outperforms, the first-order beneficiaries are the suppliers with high-confidence relationships and the customers that rely on the company's output. If ORANY struggles, the exposed names are the counterparties with fewer alternate channels or relationships that appear repeatedly in the filing trail.

This is the practical use case: map the counterparties, separate confirmed relationships from weak ones, and watch for new filings that change the direction or concentration of exposure.

The most important follow-up is not simply whether a counterparty appears once. It is whether the same relationship persists across filings, appears in risk-factor language, or connects to revenue, procurement, capacity, or delivery obligations. Those are the details that turn a graph edge into investable supply chain intelligence.

What to watch

  • New or removed supplier names in future filings.
  • Customer concentration language that points to revenue dependence.
  • Confidence changes in the ChainSifter graph as new evidence is processed.